CHPA
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association requests 30 minutes to address the Nonprescription Drugs Advisory Committee during its meeting on Sept. 25. In its letter to FDA, CHPA attached rough guidelines as discussed at a February 2005 FDA roundtable regarding consumer behavior. CHPA said it has used the information from the roundtable and May 2005 Regulatory and Scientific Conference in "formulating our recommendations for refining the evaluation of studies to support marketing approval of OTC products." Former CHPA VP-Regulatory & Scientific Affairs Douglas Bierer will represent CHPA at the meeting. FDA announced the agenda of its NDAC meeting in Aug. 28 briefing documents (1"The Tan Sheet" Sept. 4, 2006, p. 3)...
You may also be interested in...
Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation
FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.